Pharvaris N.V. (NASDAQ:PHVS) Receives $37.17 Average Price Target from Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $37.1667.

A number of research analysts recently issued reports on the stock. Bank of America upgraded shares of Pharvaris from an “underperform” rating to a “neutral” rating and boosted their target price for the company from $16.00 to $27.00 in a research report on Thursday, October 9th. JMP Securities dropped their price objective on shares of Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 13th. Zacks Research raised shares of Pharvaris from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. HC Wainwright assumed coverage on Pharvaris in a research report on Wednesday, October 15th. They issued a “buy” rating and a $60.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Wednesday, October 8th.

Hedge Funds Weigh In On Pharvaris

A number of large investors have recently modified their holdings of the company. TD Asset Management Inc lifted its holdings in shares of Pharvaris by 41.5% in the 1st quarter. TD Asset Management Inc now owns 78,122 shares of the company’s stock worth $1,227,000 after purchasing an additional 22,906 shares in the last quarter. Deutsche Bank AG lifted its stake in shares of Pharvaris by 55.1% in the first quarter. Deutsche Bank AG now owns 28,174 shares of the company’s stock valued at $442,000 after buying an additional 10,006 shares in the last quarter. Palumbo Wealth Management LLC lifted its stake in shares of Pharvaris by 3.2% in the second quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock valued at $256,000 after buying an additional 447 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new position in shares of Pharvaris during the second quarter valued at about $57,000. Finally, Geode Capital Management LLC increased its position in shares of Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after acquiring an additional 15,769 shares in the last quarter.

Pharvaris Price Performance

NASDAQ PHVS opened at $22.63 on Friday. The stock has a market capitalization of $1.18 billion, a P/E ratio of -6.74 and a beta of -2.78. The business has a 50 day simple moving average of $23.03 and a 200 day simple moving average of $20.49. Pharvaris has a one year low of $11.51 and a one year high of $26.33.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.07). Equities analysts expect that Pharvaris will post -2.71 earnings per share for the current year.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.